Earnings Momentum Strategies Dominate in Europe…
With >50% of European stocks seeing positive earnings revisions YTD, we review the efficacy of investing in consensus earnings momentum (EM) strategies relative to price momentum (PM) strategies. We adapt a method
employed by Chordia and Shivakumar (2006) to show that in Europe over the past decade, the excess returns generated by PM strategies are subsumed by earnings momentum. The reverse is not true. Effectively
therefore, “an investor who wants to trade momentum would lose nothing by completely ignoring price momentum” (Novy-Marx, 2015).
…But Be Aware of Embedded Sector Tilts
There are clear sector biases in an unconstrained earnings revisions strategy. At its most extreme, we observe that up to 60% of the long leg of the 1m FY2 earnings revisions strategy has been comprised of just three sectors. We find that both GS’ Eurozone Current Activity Indicator & the performance of GS Commodity index are strong lead indicators for sector skews in our preferred EM strategy (based on 1m FY2 consensus revisions).
Boosting Price Momentum Performance using Earnings Revisions
Over the past decade, buying stocks that combine strong 12m-1m price momentum (our preferred PM strategy) and strong 1m FY2 consensus earnings revisions has delivered higher annualized returns than a 12m-1m PM strategy. We find that the information ratio of the PM strategy is also boosted by adding a 1m FY2 revisions overlay, albeit with higher turnover.
- Brokerage says PPG’s offer of EU90/share undervalues Akzo; expects PPG will remain friendly and raise its offer
- PPG could pay EU100/share, which would increase the multiple to 9.2x, a very attractive multiple for PPG shareholders
- Management under pressure to create value for investors; ABN Amro expects cost savings program of at least EU200m
- Estimates proceeds of EU8.5b from pending separation of Specialty Chemicals, could be used for acquisitions in Coatings
- ABN Amro also raises Solvay to hold vs sell, PT EU115 vs EU110
- Expects co. will increase its exposure to specialty chemicals; M&A strategy not creating value yet
- Says favors Akzo Nobel, DSM, Tessenderlo, Umicore among chemicals; has neutral view on BASF, Brenntag, IMCD, Solvay
The news service had earlier reported that the CJ Group was seeking proposals in early March to hire financial advisors for The Body Shop bid.
While CJ Corp [KRX:001040], which supervises the core M&A of the group as a holding company, is likely to lead the deal, the specific bidding entity may be finalized at a later stage, one of the sources said.
Separately, LG Household & Healthcare (LG H&H) [KRX: 051900], is not interested in acquiring The Body Shop, a company spokesperson told this news service.
The company was reviewing the target, but did not find the target a strategic fit, two sector advisors said. It also prefers a smaller deal size.
LG H&H was mentioned as a potential buyer of The Body Shop in local media reports in February.
The Body Shop has drawn several financial investors including Bain Capital, Advent International, Clayton Dubilier & Rice (CD&R) and KKR [NYSE:KKR]. Apax, Carlyle [NASDAQ:CG], CVC Capital Partners, BC Partners, PAI Partners and American retail store operator Bed Bath & Beyond also have been mentioned as potential buyers.
L’Oreal expects EUR 1bn (USD 753m) for the deal, but its potential bidders value the deal approximately EUR 700m given the potential turnaround work required, as reported.